Having had the life-changing opportunity to undergo MDMA-assisted therapy and explore advanced therapeutic approaches to PTSD (such as IFS and EMDR), I was able to heal from the profound effects of extreme early childhood trauma. This transformative experience ignited my deep fascination with the evolving field of psychedelic science, particularly a groundbreaking class of compounds known as "entactogens" (or "empathogens"). These compounds modulate activity in the amygdala, diminishing fear responses, cultivating a sense of safety and trust, and creating profound emotional openness that allows individuals to rediscover their true selves—liberated from the false narrative shaped by trauma. The state induced by entactogens also promotes neuroplasticity—the brain’s remarkable ability to reorganize itself by forming new neural pathways, creating a foundation for lasting emotional resilience and well-being.

Building on my investments in psychedelic startups, and my passion for advancing these compounds, I am now applying my expertise as a storyteller and content strategist to collaborate with renowned neuroscientist and data scientist Dr. Matt Baggott and his partner, Luke Pustejovsky, through their innovative pharma-tech startup, Tactogen. Tactogen is pioneering a new generation of entactogens from a distinct chemical class known as benzofurans. These compounds are engineered to surpass MDMA in safety and efficacy while addressing systemic barriers to equitable access. We believe they have the potential to treat a broad range of mental health conditions beyond PTSD, all of which are linked to the dysregulation of the autonomic nervous system often rooted in trauma.

As Tactogen progresses through its Series A funding round and prepares for clinical trials in 2025, I am building the strategy behind the development and dissemination of narratives that highlight the transformative potential of next-generation entactogens. Rather than merely advancing Tactogen’s mission, these narratives are designed to foster a broader cultural conversation about the role of psychedelic science in improving human flourishing. This approach emphasizes listening to and collaborating with diverse stakeholders—including patients, clinicians, and communities—to build trust and shared understanding. By participating in this ongoing dialogue, we aim to contribute to a deeper societal awareness of the opportunity these compounds represent for mental health and well-being.